Singular Health Group Ltd, a medical technology company, develops and commercializes volumetric rendering platform (VRP) for the 3D and virtual reality (VR) visualization of anatomy using standard radiological imagery.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.21|
|52 Week High||AU$0.16|
|52 Week Low||AU$0.75|
|1 Month Change||-17.65%|
|3 Month Change||-26.32%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-44.74%|
Recent News & Updates
Singular Health Group (ASX:SHG) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
|SHG||AU Healthcare Services||AU Market|
Return vs Industry: Insufficient data to determine how SHG performed against the Australian Healthcare Services industry.
Return vs Market: Insufficient data to determine how SHG performed against the Australian Market.
Stable Share Price: SHG is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: SHG's weekly volatility (11%) has been stable over the past year.
About the Company
Singular Health Group Ltd, a medical technology company, develops and commercializes volumetric rendering platform (VRP) for the 3D and virtual reality (VR) visualization of anatomy using standard radiological imagery. It offers 3Dicom Viewer, a cross-platform application that allows its users to interact with standard 2D medical images; 3DicomVSP, an end-to-surgical planning platform; Health Academy, a scalable multi-lingual platform that provides templated curriculum aligned lessons; and GeoVR, a cloud platform for use in the mineral resources sector. The company was founded in 2017 and is headquartered in Subiaco, Australia.
Singular Health Group Fundamentals Summary
|SHG fundamental statistics|
Is SHG overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SHG income statement (TTM)|
|Cost of Revenue||AU$189.77k|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.043|
|Net Profit Margin||-976.48%|
How did SHG perform over the long term?See historical performance and comparison
Is Singular Health Group undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SHG's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate SHG's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: SHG is unprofitable, so we can't compare its PE Ratio to the Global Healthcare Services industry average.
PE vs Market: SHG is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SHG's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SHG is overvalued based on its PB Ratio (4.2x) compared to the AU Healthcare Services industry average (4.1x).
How is Singular Health Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Singular Health Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Singular Health Group performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: SHG is currently unprofitable.
Growing Profit Margin: SHG is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if SHG's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare SHG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SHG is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (39.5%).
Return on Equity
High ROE: SHG has a negative Return on Equity (-87.68%), as it is currently unprofitable.
How is Singular Health Group's financial position?
Financial Position Analysis
Short Term Liabilities: SHG's short term assets (A$4.3M) exceed its short term liabilities (A$260.6K).
Long Term Liabilities: SHG's short term assets (A$4.3M) exceed its long term liabilities (A$84.5K).
Debt to Equity History and Analysis
Debt Level: SHG's debt to equity ratio (0.03%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if SHG's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: SHG's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if SHG's interest payments on its debt are well covered by EBIT.
What is Singular Health Group current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SHG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SHG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SHG's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SHG's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SHG's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. Thomas Hanly, B.A. is Managing Director and Chief Executive Officer at Singular Health Group Limited and serves its Director since February 20, 2020. He serves as Non-Executive Director of Mineral Fert...
Experienced Board: SHG's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: SHG only recently listed within the past 12 months.
Singular Health Group Ltd's employee growth, exchange listings and data sources
- Name: Singular Health Group Ltd
- Ticker: SHG
- Exchange: ASX
- Founded: 2017
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: AU$20.560m
- Shares outstanding: 102.80m
- Website: https://singular.health
- Singular Health Group Ltd
- 3/26 Railway Road
- Western Australia
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/20 07:05|
|End of Day Share Price||2021/10/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.